Key Points
- Palisade Bio director Robert Jr. Baltera bought shares twice, purchasing 20,000 shares for $39,600 on July 1 and another 10,000 shares for $19,800 on July 2 at $1.98 each. After the trades, he owned 356,904 shares, a 5.94% increase in his position.
- The stock rose 3.7% and opened at $2.12, near its 50-day and 200-day moving averages of $1.91. Palisade Bio now has a market cap of about $367.1 million and a 52-week range of $0.53 to $2.86.
- Wall Street sentiment is broadly positive, with analysts assigning a consensus “Buy” rating and an average target price of $8.83. The company recently missed quarterly EPS estimates by $0.01, reporting a loss of $0.05 per share.
Palisade Bio, Inc. (NASDAQ:PALI - Get Free Report) Director Robert Jr. Baltera acquired 10,000 shares of the stock in a transaction on Thursday, July 2nd. The shares were purchased at an average cost of $1.98 per share, with a total value of $19,800.00. Following the transaction, the director directly owned 366,904 shares of the company's stock, valued at approximately $726,469.92. This trade represents a 2.80% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Robert Jr. Baltera also recently made the following trade(s):
- On Wednesday, July 1st, Robert Jr. Baltera bought 20,000 shares of Palisade Bio stock. The stock was acquired at an average cost of $1.98 per share, for a total transaction of $39,600.00.
Palisade Bio Stock Performance
Shares of Palisade Bio stock traded up $0.07 during trading on Tuesday, hitting $2.12. The company's stock had a trading volume of 318,176 shares, compared to its average volume of 4,084,679. The company has a fifty day simple moving average of $1.91 and a two-hundred day simple moving average of $1.91. The company has a market capitalization of $367.12 million, a PE ratio of -2.09 and a beta of 1.50. Palisade Bio, Inc. has a 52 week low of $0.53 and a 52 week high of $2.86.
Palisade Bio (NASDAQ:PALI - Get Free Report) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01). As a group, analysts predict that Palisade Bio, Inc. will post -0.25 EPS for the current year.
Institutional Trading of Palisade Bio
Several large investors have recently modified their holdings of PALI. Perceptive Advisors LLC purchased a new stake in Palisade Bio during the fourth quarter valued at $28,318,000. Commodore Capital LP bought a new stake in shares of Palisade Bio during the 4th quarter valued at about $26,896,000. Janus Henderson Group PLC grew its stake in shares of Palisade Bio by 1.4% during the 1st quarter. Janus Henderson Group PLC now owns 10,689,452 shares of the company's stock valued at $18,760,000 after purchasing an additional 149,118 shares during the period. Octagon Capital Advisors LP increased its position in shares of Palisade Bio by 7.4% during the 1st quarter. Octagon Capital Advisors LP now owns 10,276,317 shares of the company's stock valued at $17,984,000 after purchasing an additional 708,419 shares during the last quarter. Finally, RA Capital Management L.P. purchased a new stake in shares of Palisade Bio during the 4th quarter valued at about $16,742,000. Institutional investors own 11.79% of the company's stock.
Analysts Set New Price Targets
A number of research firms recently weighed in on PALI. LADENBURG THALM/SH SH raised Palisade Bio to a "strong-buy" rating in a research report on Thursday, June 25th. Oppenheimer set a $7.00 target price on Palisade Bio in a research note on Tuesday, June 30th. HC Wainwright reaffirmed a "buy" rating and issued a $2.00 price target on shares of Palisade Bio in a research report on Tuesday, June 30th. Wall Street Zen upgraded shares of Palisade Bio from a "sell" rating to a "hold" rating in a research note on Sunday. Finally, Weiss Ratings raised shares of Palisade Bio from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday, June 29th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $8.83.
Check Out Our Latest Report on PALI
About Palisade Bio
(
Get Free Report)
Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.
The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
